吲哚布芬联合氯吡格雷对比阿司匹林联合氯吡格雷在药物洗脱支架植入后的随机非劣效性试验(OPTION)
OPTION试验在中国103个中心随机纳入4551例肌钙蛋白阴性且接受药物洗脱支架植入的患者,比较吲哚布芬联合氯吡格雷与阿司匹林联合氯吡格雷的双联抗血小板治疗。1年主要终点事件发生率吲哚布芬组为4.47%,阿司匹林组为6.11%(绝对差异-1.63%,非劣效P<0.001;HR 0.73,95%CI 0.56-0.94;P=0.015),主要归因于BARC 2、3或5型出血减少(2.97% vs 4.71%;HR 0.63,95%CI 0.46-0.85;P=0.002),缺血事件无增加。
要点
- 吲哚布芬联合氯吡格雷较阿司匹林联合氯吡格雷显著降低1年净临床不良事件风险。
- 获益主要来自BARC 2、3或5型出血减少,尤其是2型出血。
- 缺血事件(心血管死亡、心梗、卒中、支架血栓)两组无显著差异。
核心结论
- 在中国肌钙蛋白阴性且接受药物洗脱支架植入的患者中,吲哚布芬联合氯吡格雷较阿司匹林联合氯吡格雷显著降低1年净临床结局风险,主要由出血事件减少驱动,缺血事件未增加。
研究设计与样本
- 随机、开放标签、终点盲法、非劣效性试验,在中国103个心血管中心纳入4551例肌钙蛋白阴性接受药物洗脱支架植入的患者,1:1随机分配至吲哚布芬组(2258例)或常规组(2293例)。
主要发现
- 主要终点(1年心血管死亡、非致死性心肌梗死、缺血性卒中、明确或可能的支架血栓或BARC 2、3或5型出血复合)吲哚布芬组101例(4.47%),常规组140例(6.11%),绝对差异-1.63%(非劣效P<0.001;HR 0.73,95%CI 0.56-0.94;P=0.015)。
- 心血管死亡、非致死性心肌梗死、缺血性卒中、支架血栓发生率吲哚布芬组分别为0.13%、0.40%、0.80%、0.22%,常规组分别为0.17%、0.44%、0.83%、0.17%(所有P>0.05)。
- BARC 2、3或5型出血发生率吲哚布芬组2.97%,常规组4.71%(HR 0.63,95%CI 0.46-0.85;P=0.002),其中2型出血吲哚布芬组1.68%,常规组3.49%(HR 0.48,95%CI 0.33-0.70;P<0.001)。
关键数值与推荐
- 吲哚布芬组方案:吲哚布芬100 mg每日两次联合氯吡格雷75 mg/d,持续12个月。
- 常规组方案:阿司匹林100 mg/d联合氯吡格雷75 mg/d,持续12个月。
- 主要终点为1年心血管死亡、非致死性心肌梗死、缺血性卒中、明确或 probable 支架血栓或BARC 2、3或5型出血的复合终点。
临床怎么用
- 对于肌钙蛋白阴性且接受药物洗脱支架植入的患者,可考虑使用吲哚布芬联合氯吡格雷作为阿司匹林联合氯吡格雷的替代双联抗血小板方案,以降低出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin as a background therapy has become the standard care after percutaneous coronary intervention. However, some adverse noncardiac effects limited the use of aspirin in clinical practice. Thus, evaluation of pharmacological alternatives to aspirin is attractive. Previous data indicated that indobufen could lessen the unwanted side effects of aspirin while retaining the antithrombotic efficacy, but its combination with a P2Y12 inhibitor still lacks randomized clinical trial evidence. METHODS: In this randomized, open-label, noninferiority trial, patients with negative cardiac troponin undergoing coronary drug-eluting stent implantation were randomly assigned in a 1:1 ratio to receive either indobufen-based DAPT (indobufen 100 mg twice a day plus clopidogrel 75 mg/d for 12 months) or conventional DAPT (aspirin 100 mg/d plus clopidogrel 75 mg/d for 12 months). The primary end point was a 1-year composite of cardiovascular death, nonfatal myocardial infarction, ischemic stroke, definite or probable stent thrombosis, or Bleeding Academic Research Consortium criteria type 2, 3, or 5 bleeding. The end points were adjudicated by an independent Clinical Event Committee. RESULTS: Between January 11, 2018, and October 12, 2020, 4551 patients were randomized in 103 cardiovascular centers: 2258 patients to the indobufen-based DAPT group and 2293 to the conventional DAPT group. The primary end point occurred in 101 patients (4.47%) in the indobufen-based DAPT group and 140 patients (6.11%) in the conventional DAPT group (absolute difference, -1.63%; Pnoninferiority<0.001; hazard ratio, 0.73 [95% CI, 0.56-0.94]; P=0.015). Cardiovascular death, nonfatal myocardial infarction, ischemic stroke, and stent thrombosis were observed in 0.13%, 0.40%, 0.80%, and 0.22% of patients in the indobufen-based DAPT group and 0.17%, 0.44%, 0.83%, and 0.17% of patients in the conventional DAPT group (all P>0.05). The occurrence of Bleeding Academic Research Consortium criteria type 2, 3, or 5 bleeding events was lower in the indobufen-based DAPT group compared with the conventional DAPT group (2.97% versus 4.71%; hazard ratio, 0.63 [95% CI, 0.46-0.85]; P=0.002), with the main decrease in type 2 bleeding (1.68% versus 3.49%; hazard ratio, 0.48 [95% CI, 0.33-0.70]; P<0.001). CONCLUSIONS: In Chinese patients with negative cardiac troponin undergoing drug-eluting stent implantation, indobufen plus clopidogrel DAPT compared with aspirin plus clopidogrel DAPT significantly reduced the risk of 1-year net clinical outcomes, which was driven mainly by a reduction in bleeding events without an increase in ischemic events. REGISTRATION: URL: https://www.chictr.org.cn; Unique identifier: ChiCTR-IIR-17013505.
引用
- Wu H, Xu L, Zhao X, et al. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial. Circulation. 2022. PMID: 36335890. doi:10.1161/CIRCULATIONAHA.122.062762
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。